Tel Aviv, Israel March 18, 2018 – MedyMatch Technology, a company focused on assisting physicians provide accurate patient assessment through artificial intelligence-based insights, (which recently received FDA Breakthrough Designation for its intracranial hemorrhage (ICH) detection application), announced today an exciting new phase in its growth with the launch of its new corporate identity as MaxQ AI.
“Today we launch the MaxQ AI brand to reflect a new day in the company’s journey in bringing artificial intelligence-based clinical applications to the marketplace,” said Gene Saragnese, Chairman & CEO of MaxQ AI. “The healthcare industry is at an inflection point, at a “Max Q” (a point of maximum pressure) – we believe AI has the potential to fundamentally reinvent healthcare as we know it, to deliver accurate and cost-effective patient care to billions of people around the world.”
MaxQ AI has developed a broad machine vision and deep learning platform to support the assessment of multiple clinical indications. The Company’s team of AI, deep learning and machine vision experts are working with world-class clinical and industry partners to yield unprecedented insights into medical data. The first of these applications will be the detection of intracranial hemorrhage. Accurate and timely detection of ICH is a critical step in clinical decision making for stroke assessment and head trauma. Working with its development and distribution partners, MaxQ AI is on a mission to make all caregivers confident, life-saving experts every time and in all locations through AI-enabled clinical decision support at the point of care.
About MaxQ AI
Formerly known as MedyMatch Technology, based in Tel Aviv, Israel, MaxQ AI is a leading medical artificial intelligence company delivering a clinical decision support platform to improve patient outcomes in acute medical scenarios. The platform can be natively integrated into PACS systems, medical imaging hardware, or healthcare clouds. To learn more, please visit www.maxq.ai.